FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044422681> ?p ?o ?g. }

• W2044422681 endingPage "AB34" @default.
• W2044422681 startingPage "AB34" @default.
• W2044422681 abstract "RATIONALE: High exposure to microbes or microbial compounds (e.g. lipopolysaccharides, LPS) is associated with lower prevalence rates of atopy in children from rural areas (“farm effect”). Aim of this trial was to evaluate the effect of an orally applied bacterial lysate in infancy on the prevalence of atopic eczema (AE) in the first year of life.METHODS: In a double-blind placebo-controlled trial, 553 healthy infants with at least single positive heredity for atopy were treated daily from week 5 until the end of month 7 by oral route with bacterial lysate (Pro-Symbioflor) containing heat-killed gram-negative E. coli and grampositive Enterococcus faecalis (1.5-4.5 × 107 bacteria/ml). Children were followed until 3 years of age. Primary outcome was the prevalence of atopic eczema (AE) at the end of the treatment period at 7 months of age.RESULTS: 526 completed the study until 7 months and 483 children until 3 years of age. At 7 months, 40 children in the treatment group (15.8%) and 55 children in the placebo group (20.1%) had developed eczema (n.s.). Only in the group of children with atopic fathers, there was a highly significant difference for the prevalence of AE (ITT set after worst prevalence imputation 7.4% and 29.8%, respectively; Fisher`s exact test p=0.00169).CONCLUSIONS: There was no treatment effect in the whole study group, however, in a subpopulation of children with only paternal heredity for atopy, feeding of bacterial lysates may prevent the development of AE, possibly indicating a preventive effect only in subjects with a ristricted risk for atopy. RATIONALE: High exposure to microbes or microbial compounds (e.g. lipopolysaccharides, LPS) is associated with lower prevalence rates of atopy in children from rural areas (“farm effect”). Aim of this trial was to evaluate the effect of an orally applied bacterial lysate in infancy on the prevalence of atopic eczema (AE) in the first year of life. METHODS: In a double-blind placebo-controlled trial, 553 healthy infants with at least single positive heredity for atopy were treated daily from week 5 until the end of month 7 by oral route with bacterial lysate (Pro-Symbioflor) containing heat-killed gram-negative E. coli and grampositive Enterococcus faecalis (1.5-4.5 × 107 bacteria/ml). Children were followed until 3 years of age. Primary outcome was the prevalence of atopic eczema (AE) at the end of the treatment period at 7 months of age. RESULTS: 526 completed the study until 7 months and 483 children until 3 years of age. At 7 months, 40 children in the treatment group (15.8%) and 55 children in the placebo group (20.1%) had developed eczema (n.s.). Only in the group of children with atopic fathers, there was a highly significant difference for the prevalence of AE (ITT set after worst prevalence imputation 7.4% and 29.8%, respectively; Fisher`s exact test p=0.00169). CONCLUSIONS: There was no treatment effect in the whole study group, however, in a subpopulation of children with only paternal heredity for atopy, feeding of bacterial lysates may prevent the development of AE, possibly indicating a preventive effect only in subjects with a ristricted risk for atopy." @default.
• W2044422681 created "2016-06-24" @default.
• W2044422681 creator A5009731868 @default.
• W2044422681 creator A5036729938 @default.
• W2044422681 creator A5042301272 @default.
• W2044422681 creator A5054596261 @default.
• W2044422681 creator A5061729044 @default.
• W2044422681 creator A5063358719 @default.
• W2044422681 creator A5078669784 @default.
• W2044422681 creator A5081484175 @default.
• W2044422681 creator A5082232958 @default.
• W2044422681 creator A5083725831 @default.
• W2044422681 creator A5084094427 @default.
• W2044422681 date "2011-02-01" @default.
• W2044422681 modified "2023-10-03" @default.
• W2044422681 title "Oral Application Of Bacterial Lysate In Infancy Decreases The Risk Of Infantile Atopic Eczema In A Subgroup Of Children With Paternal Atopy" @default.
• W2044422681 doi "https://doi.org/10.1016/j.jaci.2010.12.146" @default.
• W2044422681 hasPublicationYear "2011" @default.
• W2044422681 type Work @default.
• W2044422681 sameAs 2044422681 @default.
• W2044422681 citedByCount "1" @default.
• W2044422681 countsByYear W20444226812012 @default.
• W2044422681 crossrefType "journal-article" @default.
• W2044422681 hasAuthorship W2044422681A5009731868 @default.
• W2044422681 hasAuthorship W2044422681A5036729938 @default.
• W2044422681 hasAuthorship W2044422681A5042301272 @default.
• W2044422681 hasAuthorship W2044422681A5054596261 @default.
• W2044422681 hasAuthorship W2044422681A5061729044 @default.
• W2044422681 hasAuthorship W2044422681A5063358719 @default.
• W2044422681 hasAuthorship W2044422681A5078669784 @default.
• W2044422681 hasAuthorship W2044422681A5081484175 @default.
• W2044422681 hasAuthorship W2044422681A5082232958 @default.
• W2044422681 hasAuthorship W2044422681A5083725831 @default.
• W2044422681 hasAuthorship W2044422681A5084094427 @default.
• W2044422681 hasBestOaLocation W20444226811 @default.
• W2044422681 hasConcept C126322002 @default.
• W2044422681 hasConcept C142724271 @default.
• W2044422681 hasConcept C187212893 @default.
• W2044422681 hasConcept C203014093 @default.
• W2044422681 hasConcept C204787440 @default.
• W2044422681 hasConcept C207480886 @default.
• W2044422681 hasConcept C27081682 @default.
• W2044422681 hasConcept C2777697326 @default.
• W2044422681 hasConcept C2778329239 @default.
• W2044422681 hasConcept C71924100 @default.
• W2044422681 hasConceptScore W2044422681C126322002 @default.
• W2044422681 hasConceptScore W2044422681C142724271 @default.
• W2044422681 hasConceptScore W2044422681C187212893 @default.
• W2044422681 hasConceptScore W2044422681C203014093 @default.
• W2044422681 hasConceptScore W2044422681C204787440 @default.
• W2044422681 hasConceptScore W2044422681C207480886 @default.
• W2044422681 hasConceptScore W2044422681C27081682 @default.
• W2044422681 hasConceptScore W2044422681C2777697326 @default.
• W2044422681 hasConceptScore W2044422681C2778329239 @default.
• W2044422681 hasConceptScore W2044422681C71924100 @default.
• W2044422681 hasIssue "2" @default.
• W2044422681 hasLocation W20444226811 @default.
• W2044422681 hasOpenAccess W2044422681 @default.
• W2044422681 hasPrimaryLocation W20444226811 @default.
• W2044422681 hasRelatedWork W1973244168 @default.
• W2044422681 hasRelatedWork W1978667290 @default.
• W2044422681 hasRelatedWork W2089319093 @default.
• W2044422681 hasRelatedWork W2390666774 @default.
• W2044422681 hasRelatedWork W2407094426 @default.
• W2044422681 hasRelatedWork W2407394122 @default.
• W2044422681 hasRelatedWork W2474132265 @default.
• W2044422681 hasRelatedWork W2751473327 @default.
• W2044422681 hasRelatedWork W2809102849 @default.
• W2044422681 hasRelatedWork W4312185357 @default.
• W2044422681 hasVolume "127" @default.
• W2044422681 isParatext "false" @default.
• W2044422681 isRetracted "false" @default.
• W2044422681 magId "2044422681" @default.
• W2044422681 workType "article" @default.